Literature DB >> 11221852

Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.

S Hiratsuka1, Y Maru, A Okada, M Seiki, T Noda, M Shibuya.   

Abstract

Vascular endothelial growth factor (VEGF) and its two receptors, Fms-like tyrosine kinase 1 (Flt-1) (VEGFR-1) and KDR/Flk-1 (VEGFR-2), have been demonstrated to be an essential regulatory system for blood vessel formation in mammals. KDR is a major positive signal transducer for angiogenesis through its strong tyrosine kinase activity. Flt-1 has a unique biochemical activity, 10-fold higher affinity to VEGF, whereas much weaker tyrosine kinase activity compared with KDR. Recently, we and others have shown that Flt-1 has a negative regulatory function for physiological angiogenesis in the embryo, possibly with its strong VEGF-trapping activity. However, it is still open to question whether the tyrosine kinase of Flt-1 has any positive role in angiogenesis at adult stages. In this study, we examined whether Flt-1+ could be a positive signal transducer under certain pathological conditions, such as angiogenesis with tumors overexpressing a Flt-1-specific, VEGF-related ligand. Our results show clearly that murine Lewis lung carcinoma cells overexpressing placenta growth factor-2, an Flt-1-specific ligand, grew in wild-type mice much faster than in Flt-1 tyrosine kinase domain-deficient mice. Blood vessel formation in tumor tissue was higher in wild-type mice than in Flt-1 tyrosine kinase-deficient mice. On the other hand, the same carcinoma cells overexpressing VEGF showed no clear difference in the tumor growth rate between these two genotypes of mice. These results indicate that Flt-1 is a positive regulator using its tyrosine kinase under pathological conditions when the Flt-1-specific ligand is abnormally highly expressed. Thus, Flt-1 has a dual function in angiogenesis, acting in a positive or negative manner in different biological conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221852

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  75 in total

Review 1.  Cellular and molecular mechanisms of embryonic haemangiogenesis and lymphangiogenesis.

Authors:  Jörg Wilting; Bodo Christ; Li Yuan; Anne Eichmann
Journal:  Naturwissenschaften       Date:  2003-09-17

2.  VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

Authors:  Jianying Dong; Jeremy Grunstein; Max Tejada; Frank Peale; Gretchen Frantz; Wei-Ching Liang; Wei Bai; Lanlan Yu; Joe Kowalski; Xiaohuan Liang; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

Review 3.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

4.  PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.

Authors:  Joao Incio; Josh Tam; Nuh N Rahbari; Priya Suboj; Dan T McManus; Shan M Chin; Trupti D Vardam; Ana Batista; Suboj Babykutty; Keehoon Jung; Anna Khachatryan; Tai Hato; Jennifer A Ligibel; Ian E Krop; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Masabumi Shibuya; Peter Carmeliet; Raquel Soares; Dan G Duda; Rakesh K Jain; Dai Fukumura
Journal:  Clin Cancer Res       Date:  2016-02-09       Impact factor: 12.531

5.  A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network.

Authors:  Daniel Menendez; Oliver Krysiak; Alberto Inga; Bianca Krysiak; Michael A Resnick; Gilbert Schönfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

6.  FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression.

Authors:  Leah A Owen; Margaux A Morrison; Jeeyun Ahn; Se Joon Woo; Hajime Sato; Rosann Robinson; Denise J Morgan; Fani Zacharaki; Marina Simeonova; Hironori Uehara; Usha Chakravarthy; Ruth E Hogg; Balamurali K Ambati; Maria Kotoula; Wolfgang Baehr; Neena B Haider; Giuliana Silvestri; Joan W Miller; Evangelia E Tsironi; Lindsay A Farrer; Ivana K Kim; Kyu Hyung Park; Margaret M DeAngelis
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-08       Impact factor: 4.799

7.  Anti-SPARC oligopeptide inhibits laser-induced CNV in mice.

Authors:  Hironori Uehara; Ling Luo; Jacquelyn Simonis; Nirbhai Singh; Ethan Will Taylor; Balamurali K Ambati
Journal:  Vision Res       Date:  2009-12-22       Impact factor: 1.886

8.  Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma.

Authors:  Nibal Zaghloul; Sonia L Hernandez; Jae-O Bae; Jianzhong Huang; Jason C Fisher; Alice Lee; Angela Kadenhe-Chiweshe; Jessica J Kandel; Darrell J Yamashiro
Journal:  Int J Oncol       Date:  2009-02       Impact factor: 5.650

9.  Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity.

Authors:  Shu-Ching Shih; Meihua Ju; Nan Liu; Lois E H Smith
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 10.  Therapeutic potential of manipulating VEGF splice isoforms in oncology.

Authors:  Emma S Rennel; Steven J Harper; David O Bates
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.